A skin improvement is not yet a psoriasis treatment claim
Research into GLP-1 medicines and psoriasis is interesting because some people have both psoriasis and metabolic conditions. But a medicine helping someone’s weight or diabetes does not establish that it treats their skin disease. The published studies also ask different questions: some study liraglutide in people without diabetes, while others study semaglutide or liraglutide alongside diabetes care. I would read each result with its population and comparison attached. A positive small study can justify a better trial without establishing that every medicine in the class will improve psoriasis. The useful clinical question is how to coordinate existing care while the evidence develops.[1] For the study-design questions behind these differences, read how to read GLP-1 research.
One placebo-controlled liraglutide trial did not show a skin benefit
A randomized placebo-controlled study published in 2015 enrolled twenty glucose-tolerant patients with plaque psoriasis and followed treatment for eight weeks. Liraglutide produced more weight loss, but the difference in the psoriasis severity score, PASI, was not statistically significant. Quality-of-life results also did not differ significantly. That is an important counterweight to accounts that describe only improvement. It does not prove that GLP-1 treatment can never help psoriasis; the trial was small and short. It does show why weight reduction and skin improvement should not be collapsed into one result. A positive weight outcome did not automatically produce the claimed dermatologic benefit in this particular comparison.[1]
| Study detail | What was measured |
|---|---|
| Participants | 20 glucose-tolerant patients with plaque psoriasis |
| Design and duration | Liraglutide versus placebo for eight weeks |
| Skin outcome | PASI change did not significantly differ between groups |
| Other outcome | Weight loss favored liraglutide; skin benefit did not follow automatically |
This table describes one small trial, not a pooled result or proof of no effect in every population. Source: Faurschou et al.: placebo-controlled liraglutide trial.
A different small trial in diabetes reported improvement
Lin and colleagues randomized twenty-five people with psoriasis and type 2 diabetes to a liraglutide group or control group for twelve weeks. They reported improvements in psoriasis severity, dermatology-related quality of life and several skin inflammatory measures. The finding supports further research in that specific setting, but it does not erase the earlier placebo-controlled result in people without diabetes. Differences in patient selection, treatment context and study design make a universal class conclusion premature. A change in an inflammatory marker also does not independently prove why the skin improved. Read the observed clinical result separately from the authors’ proposed biological explanation.[2]
The semaglutide trial is informative but still preliminary
A 2025 report described a twelve-week open-label randomized study in people with obesity, type 2 diabetes and psoriasis receiving background metformin. Thirty-one entered, with twenty-eight remaining after exclusions. The authors reported improved skin outcomes with semaglutide; two participants were excluded because of nausea or vomiting and one because of disease exacerbation. Those losses belong beside the improvement, especially in a small study. The article’s title describes a randomized trial, while its methods also call the design an interventional cohort study. That inconsistent wording and the absence of blinding reduce confidence in broad claims. This is a signal to investigate, not a definitive treatment comparison.[3]
The newer eighteen-month report adds duration, not randomization
An October 2026 single-center retrospective report followed thirty-three people with obesity and mild-to-moderate psoriasis treated with semaglutide over eighteen months. Mean PASI fell from 9.31 to 5.05, while weight-related and metabolic measures improved too. Those observations extend the timeline beyond the short trials, but there was no randomized untreated comparison in this report. It therefore cannot isolate the drug’s direct skin effect from weight change, other care or selection of patients who remained in treatment. The paper reports industry-supported medical-writing assistance, which is relevant context rather than an automatic reason to dismiss it. Longer follow-up and a larger sample answer different questions.[4]
| Reported observation | What it cannot establish |
|---|---|
| 33 patients observed for 18 months | A randomized comparison or a class-wide effect |
| Mean PASI 9.31 to 5.05 | A cure or complete clearance for every patient |
| Metabolic and skin measures changed together | Which change caused another |
Single-center retrospective semaglutide experience, published October 16, 2026; the treatment context differs from the earlier trials. Source: Proietti and Potenza: eighteen-month semaglutide observational experience, October 2026.
Do not turn PASI improvement into cure or joint-disease protection
PASI summarizes features and extent of skin involvement; a lower score is a skin-severity result. It should not be translated into proof that psoriasis is cured, that flares will not return or that psoriatic arthritis is prevented. Likewise, a group average does not show how many people achieved complete clearance unless that outcome is reported explicitly. The newer observational study began with mild or moderate skin disease, so it cannot establish results for every severity level. When reading the next headline, ask whether it reports a change from baseline, a controlled difference or a responder threshold. Those are different ways of describing benefit, with different implications.[4] A biomarker result needs its own interpretation; see our inflammation and CRP evidence guide.
Bring both prescribing teams into the same conversation
If you already have psoriasis and are considering GLP-1 treatment for another medical reason, prepare one list of your medicines, current skin treatment and the clinicians involved. Ask who will assess a new rash or flare and how changes in the skin will be documented. Do not stop an effective psoriasis treatment to test a metabolic-drug hypothesis yourself. A useful follow-up record might include the date, symptoms, photographs if your clinician requests them and changes in other treatment. That record helps frame a question without deciding the cause in advance. The research described here cannot tell an individual whether starting, continuing or switching a medicine is appropriate.[3]
Shop for coordinated care without buying a skin-outcome promise
A provider comparison can help assess access, records sharing, follow-up and total cost; it cannot establish that one commercial service will improve psoriasis more than another. If a clinician recommends a GLP-1 for an appropriate metabolic indication, ask which product has evidence for that indication and how dermatology care stays involved. Sesame Care and LifeMD are care-shopping paths to investigate for their published prescribing and support arrangements, with eligibility and product access confirmed individually. A service promising psoriasis clearance based on a small trial would be going beyond the evidence. My reading is that the topic merits further clinical research while established skin care and individualized medical decisions remain central.[2] For a practical care comparison, read the Sesame Care review and ask how your existing clinicians can stay informed. A second route to investigate is the LifeMD review with care fees and medication access kept separate.
Put the questions to work
Compare our researched providers or build your provider checklist.
Explore relevant provider reviews
Use these reviews to compare the published services and terms. Inclusion is a research starting point, not a recommendation for treatment.
Continue your research
Sources & scope
Sources checked October 25, 2026. This guide explains published information and consumer research questions; it is not a clinical evaluation.
- Faurschou et al.: placebo-controlled liraglutide trial
- Lin et al.: randomized liraglutide study in psoriasis and type 2 diabetes
- Petković-Dabić et al.: semaglutide study, Biomolecules 2025
- Proietti and Potenza: eighteen-month semaglutide observational experience, October 2026
Prices and terms can change. Confirm your specific offer directly with the provider.